Comorbid immune-mediated diseases in inflammatory bowel disease: a nation-wide population-based study.

Related Articles Comorbid immune-mediated diseases in inflammatory bowel disease: a nation-wide population-based study. Aliment Pharmacol Ther. 2018 Dec 02;: Authors: Park SW, Kim TJ, Lee JY, Kim ER, Hong SN, Chang DK, Yang M, Kim S, Shin MH, Kim YH Abstract BACKGROUND: Although a higher risk of other immune-mediated diseases has been reported in inflammatory bowel disease (IBD) patients, the risk factors of immune-mediated diseases development and the effect of concomitant immune-mediated diseases on outcomes remain poorly defined. AIM: To determine the risk factors of incident immune-mediated diseases and the…

Read More

The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn’s disease: a post hoc analysis.

Related Articles The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn’s disease: a post hoc analysis. Aliment Pharmacol Ther. 2018 Dec 02;: Authors: Hyams JS, Dubinsky M, Rosh J, Ruemmele FM, Eichner SF, Maa JF, Lazar A, Alperovich G, Mostafa NM, Robinson AM Abstract BACKGROUND: In the IMAgINE 1 study, adalimumab induced and maintained remission of moderate-to-severe Crohn’s disease in children. AIM: To assess the efficacy, pharmacokinetics, immunogenicity and safety of immunomodulator and adalimumab combination therapy vs adalimumab monotherapy in paediatric…

Read More

Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new-onset paediatric Crohn’s disease.

Related Articles Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new-onset paediatric Crohn’s disease. Aliment Pharmacol Ther. 2018 Nov 18;: Authors: Ziv-Baran T, Hussey S, Sladek M, Amil Dias J, Martin de Carpi J, Miele E, Veres G, Lionetti P, Koletzko S, Nuti F, Paerregaard A, Kolho KL, Russell RK, Shaoul R, Weiner D, Sigall Boneh R, Escher J, Finnby L, Turner D, Levine A Abstract BACKGROUND: Paediatric Crohn’s disease is characteried by frequently relapsing disease which may lead to hospitalisations…

Read More

Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids.

Related Articles Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids. Aliment Pharmacol Ther. 2018 Nov 14;: Authors: Noureldin M, Higgins PDR, Govani SM, Cohen-Mekelburg S, Kenney BC, Stidham RW, Waljee JF, Waljee AK Abstract BACKGROUND: Opioids are commonly prescribed to manage pain associated with inflammatory bowel disease (IBD). It is unknown what percentage of patients develop new persistent opioid use following a steroid-treated IBD flare. AIM: To identify the incidence and the predictors of new persistent opioid use following an IBD…

Read More

Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn’s disease of the pouch.

Related Articles Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn’s disease of the pouch. Aliment Pharmacol Ther. 2018 Nov 08;: Authors: Cummings D, Cruise M, Lopez R, Roggenbuck D, Jairath V, Wang Y, Shen B, Rieder F Abstract BACKGROUND: Zymogen granule glycoprotein 2 (GP2) is a major autoantigen of Crohn’s disease-specific pancreatic autoantibodies. AIM: To test a link between loss of tolerance to isoforms of GP2 and pouch disorders in a cross-sectional study in ulcerative colitis patients with ileal pouch-anal anastomosis (IPAA). METHODS: Serum…

Read More

Systematic review: the consequences of psychosocial effects of inflammatory bowel disease on patients’ reproductive health.

Related Articles Systematic review: the consequences of psychosocial effects of inflammatory bowel disease on patients’ reproductive health. Aliment Pharmacol Ther. 2018 Nov 08;: Authors: Purewal S, Chapman S, Czuber-Dochan W, Selinger C, Steed H, Brookes MJ Abstract BACKGROUND: High levels of voluntary childlessness and pregnancy-related fears have been reported amongst inflammatory bowel disease (IBD) patients. AIMS: To investigate what factors determine IBD patients’ childbearing decisions; and to examine psychosocial consequences of IBD on various aspects of patients’ reproductive health. METHODS: Six electronic databases were searched in a pre-specified and structured…

Read More

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.

Related Articles Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Aliment Pharmacol Ther. 2018 Nov 08;: Authors: Feagan BG, Lam G, Ma C, Lichtenstein GR Abstract BACKGROUND: Biosimilar versions of widely prescribed drugs, including the tumour-necrosis factor antagonist infliximab, are becoming increasingly available. As biosimilars are not identical copies of reference products, evidence may be required to demonstrate that switching between a reference biologic and biosimilars is safe and efficacious. To establish interchangeability, US Food and Drug Administration guidance states that studies must demonstrate that…

Read More

Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-Personalised medicine in its infancy.

Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-Personalised medicine in its infancy. Aliment Pharmacol Ther. 2018 Oct 30;: Authors: Stevens TW, Matheeuwsen M, Lönnkvist MH, Parker CE, Wildenberg ME, Gecse KB, D’Haens GR Abstract BACKGROUND: Inflammatory bowel disease (IBD) is characterised by substantial heterogeneity in treatment response. With an expanding number of therapeutic agents, identifying optimal treatment at the patient level remains a major challenge. AIM: To systematically review the available literature on predictive biomarkers of therapeutic response in IBD. METHODS: An electronic literature search was performed…

Read More

Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life.

Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. Aliment Pharmacol Ther. 2018 Oct 30;: Authors: Paschos P, Katsoula A, Salanti G, Giouleme O, Athanasiadou E, Tsapas A Abstract BACKGROUND: Patient-reported outcomes are important in the assessment of efficacy of intervention for ulcerative colitis (UC). AIM: To compare the impact of interventions for moderate-to-severe UC on health-related quality of life (HRQL). METHODS: We searched Medline, Embase, CENTRAL and grey literature sources through October 2017. We included randomised controlled trials (RCTs)…

Read More
<< Go Back